Compositions for preventing or treating menopausal syndrome of women comprising cudrania tricuspidata extract, angelica sinensis extract and lycii radicis cortex extract as an active ingredient
A combination of Cudrania tricuspidata, Angelica gigas, and Lycium chinense extracts acts as estrogen receptor agonists, addressing the need for side-effect-free treatment of menopausal symptoms by enhancing estrogenic activity and reducing uterine proliferation risks.
Patent Information
- Application Number
- KR1020220149933
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-11-10
- Filing Date
- 2022-11-10
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2042-11-10
AI Technical Summary
Existing treatments for menopausal symptoms, such as hormone replacement therapy, often come with significant side effects, and there is a need for natural alternatives that effectively alleviate these symptoms without adverse reactions.
A pharmaceutical composition and health functional food containing Cudrania tricuspidata, Angelica gigas, and Lycium chinense extracts, which act as estrogen receptor agonists, providing estrogenic activity without side effects, are developed to treat and prevent menopausal symptoms.
The mixed extract demonstrates synergistic estrogenic activity, effectively alleviating menopausal symptoms with minimal uterine proliferation side effects, making it suitable for hormone replacement therapy.
Smart Images

Figure 112022119888250-PAT00001_ABST
Abstract
Description
Technology Field
[0001] The present invention is a Cudrania tricuspidata ( Cudrania tricuspidata ) extract, Angelica ( Angelica sinensis ) extract and *Lycium chinense* bark ( Lycii Radicis Cortex The present invention relates to a pharmaceutical composition for preventing or treating menopausal symptoms containing an extract as an active ingredient, and a health functional food for preventing or improving menopausal symptoms. Background Technology
[0003] Women experience gradual onset of menopausal symptoms about 10 years before and after menopause, typically between the ages of 45 and 55, leading to physical and mental difficulties. According to statistics from the Health Insurance Review and Assessment Service, approximately 430,000 patients visited clinics for menopausal symptoms in 2013. Furthermore, as women become more active in the workforce, the onset of symptoms is gradually decreasing due to factors such as increased stress, smoking, and drinking rates, making it necessary to manage menopausal symptoms in women.
[0004] Menopause is a type of endocrine syndrome that refers to a transitional period in which physiological and sexual functions decline or disappear due to a decrease in female hormones, specifically estrogen, resulting from the overall and gradual aging of ovarian function. Symptoms of menopause include those caused by vascular changes such as hot flashes, tachycardia, sweating, or headaches; those caused by musculoskeletal changes such as muscle pain, joint pain, and lower back pain; those caused by genitourinary changes such as frequent urination or urinary incontinence; and those caused by changes in the nervous system such as memory loss, depression, decreased concentration, and dizziness. In addition, symptoms such as vision loss and changes in the skin and hair may occur, and diseases fatal to women's health, such as osteoporosis or cardiovascular disease, may develop due to hormonal changes.
[0005] Therefore, in order to improve the physical and mental health and quality of life of middle-aged women, there has been a demand for the development of treatments that can alleviate menopausal symptoms, and drugs such as hormone replacement therapy and non-steroidal anti-inflammatory drugs have been developed to alleviate these symptoms. However, most of these drugs are known to have side effects such as headaches and weight gain. In particular, estrogen replacement therapy is known to increase the risk of uterine bleeding, stroke, heart attack, breast cancer, and uterine cancer, along with rejection reactions, because it involves the artificial administration of hormones into the body.
[0006] Due to these problems, there is growing interest in replacing estrogen therapy with natural methods in the form of food or additives, and there is a demand for the development of new treatments for menopausal symptoms that are effective in alleviating symptoms without side effects.
[0008] Meanwhile, estrogen exerts various biological effects, including cell number increase and differentiation. These biological effects are exerted through estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), which belong to the nuclear receptor superfamily. The mechanism of action of estrogen receptors involves the binding of estrogen to intracellular estrogen receptors to form receptor dimers, which then regulate the expression of target genes by binding to specific estrogen response elements (EREs) located in the promoters of those genes. Since the two estrogen receptors possess different tissue distribution patterns and ligand binding affinities, these differences enable different selective roles of estrogen receptor agonists and antagonists in different tissues. In addition, substances that act on estrogen receptors are being utilized as targets for hormone replacement therapy in menopausal women and for the development of chemotherapy agents for genital cancers. Therefore, if natural substances that activate estrogen receptors are discovered that have few side effects on the human body, they can be usefully applied to the treatment and prevention of menopausal symptoms in women, and thus, related research is continuously being conducted.
[0010] Accordingly, as a result of efforts to develop a natural product-derived combination agent for treating menopausal symptoms in women that is safe for the human body, it was confirmed that a mixed extract of Cudrania tricuspidata extract, Angelica gigas extract, and Lycium chinense extract has estrogenic activity and acts as an estrogen receptor agonist without side effects, and the present invention was completed by revealing that the said mixed extract can be used as a female hormone replacement therapy agent to prevent and treat menopausal symptoms caused by estrogen deficiency in menopausal women. Prior art literature
[65535] Republic of Korea Published Patent No. 10-2015-0029852 Republic of Korea Registered Patent No. 10-2075836 Phytother. Res. 20, 665-669 The problem to be solved
[0012] The purpose of the present invention is the Cudrania tricuspidata ( Cudrania tricuspidata ) extract, Angelica ( Angelica sinensis ) extract and *Lycium chinense* bark ( Lycii Radicis Cortex The invention provides a pharmaceutical composition for preventing or treating symptoms of menopause in women, containing an extract as an active ingredient.
[0013] Another objective of the present invention is to provide a health functional food for preventing or improving symptoms of menopause in women, containing Cudrania tricuspidata extract, Angelica gigas extract, and Lycium chinense extract as active ingredients.
[0014] Another objective of the present invention is to provide a food composition for preventing or improving symptoms of menopause in women, containing Cudrania tricuspidata extract, Angelica gigas extract, and Lycium chinense extract as active ingredients. means of solving the problem
[0016] To achieve the above objective, the present invention (Cudrania tricuspidata) Cudrania tricuspidata ) extract, Angelica ( Angelica sinensis ) extract and *Lycium chinense* bark ( Lycii Radicis Cortex Provides a pharmaceutical composition for preventing or treating symptoms of menopause in women, containing an extract as an active ingredient.
[0017] The present invention provides a health functional food for preventing or improving symptoms of menopause in women, containing Cudrania tricuspidata extract, Angelica gigas extract, and Lycium chinense extract as active ingredients.
[0018] The present invention provides a food composition for preventing or improving symptoms of menopause in women, containing Cudrania tricuspidata extract, Angelica gigas extract, and Lycium chinense extract as active ingredients. Effects of the invention
[0020] The mixed extract of the Cudrania tricuspidata extract, Angelica gigas extract, and Lycium chinense extract of the present invention has estrogenic activity and acts as an estrogen receptor agonist without side effects, so it can be used in hormone replacement therapy to prevent and treat menopausal symptoms caused by estrogen deficiency in menopausal women. Brief explanation of the drawing
[0022] Figure 1 is a figure confirming the synergistic effect of the mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense of the present invention by comparing ER-mediated transcriptional activity after treating estrogen receptor-positive breast cancer cell line MCF-7 with Cudrania tricuspidata extract, Angelica gigas extract, Lycium chinense extract, or a mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense prepared by mixing in a mixing ratio showing excellent effect according to an embodiment of the present invention. Figure 2 is a figure confirming the estrogen-like activity synergistic effect of the mixed extract of Angelica gigas and Lycium chinense of the present invention by comparing the cell proliferation rates after treating estrogen receptor-positive breast cancer cell line MCF-7 with Cudrania tricuspidata extract, Angelica gigas extract, Lycium chinense extract, or a mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense prepared by mixing in a mixing ratio showing excellent effects according to an embodiment of the present invention. Figure 3 is a figure confirming the presence or absence of uterine proliferation side effects of the mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense of the present invention by comparing ER-mediated transcriptional activity after treating the endometrial cancer adenocarcinoma cell line Ishikawa with a mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense prepared by mixing at a ratio showing excellent effects according to an embodiment of the present invention at different concentrations. Specific details for implementing the invention
[0023] The present invention will be described in more detail below.
[0025] The present invention is a Cudrania tricuspidata ( Cudrania tricuspidata ) extract, Angelica ( Angelica sinensis ) extract and *Lycium chinense* bark ( Lycii Radicis CortexProvides a pharmaceutical composition for preventing or treating symptoms of menopause in women, containing an extract as an active ingredient.
[0026] Each of the active ingredients of the present invention, namely the Cudrania tricuspidata extract, the Angelica gigas extract, and the Lycium chinense extract, is preferably prepared by a method comprising the following steps, but is not limited thereto:
[0027] 1) a step of extracting by adding an extraction solvent to each of Cudrania tricuspidata, Angelica gigas, and Lycium chinense bark; and
[0028] 2) A step of filtering each of the Cudrania tricuspidata extract, Angelica gigas extract, and Lycium chinense extract from Step 1).
[0029] In the present invention, the Cudrania tricuspidata, Angelica gigas, and Lycium chinense bark of step 1) may be used as cultivated or commercially available varieties without limitation. Additionally, the flowers, branches, stems, leaves, fruits, above-ground parts, rhizomes, roots, or combinations thereof of the Cudrania tricuspidata and Angelica gigas may be used, but are not limited thereto. It is preferable that the Lycium chinense bark be a medicinal material made from the dried root bark of Lycium chinense Miller or other plants of the same genus.
[0030] In the present invention, it is preferable to use water, alcohol, or a mixture thereof as the extraction solvent in step 1). It is preferable to use a C1 to C2 lower alcohol as the alcohol, and it is preferable to use ethanol or methanol as the lower alcohol. It is preferable to use ultrasonic extraction, shaking extraction, Soxhelt extraction, or reflux extraction as the extraction method, but is not limited thereto. It is preferable to extract by adding the extraction solvent in an amount of 1 to 15 times the amount of washed and well-dried Cudrania tricuspidata, Angelica gigas, and Lycium chinense bark, and more preferable to extract by adding 2 to 10 times the amount. It is preferable to extract at an extraction temperature of 20 to 110°C, but is not limited thereto. In addition, it is preferable to extract at an amount of 10 minutes to 72 hours, and more preferable to extract at an amount of 20 minutes to 48 hours, but is not limited thereto. Furthermore, it is preferable to extract 1 to 5 times, but is not limited thereto.
[0031] In the present invention, the Cudrania tricuspidata extract, Angelica gigas extract, and Lycium chinense extract may be mixed after preparing each extract, but it is also possible to prepare the extract by mixing Cudrania tricuspidata, Angelica gigas, and Lycium chinense and then obtaining the extract thereof.
[0032] In the present invention, after undergoing step 2), the following steps may be additionally included:
[0033] 3) a step of concentrating each of the filtrates from step 2) under reduced pressure; and
[0034] 4) A step of drying each of the concentrates from step 3).
[0035] In the present invention, the vacuum concentration in step 3) is preferably performed using a vacuum vacuum concentrator or a vacuum rotary evaporator, but is not limited thereto. Additionally, drying is preferably performed by vacuum drying, vacuum drying, boiling drying, spray drying, or freeze-drying, but is not limited thereto.
[0036] In the present invention, the steps of mixing Cudrania tricuspidata, Angelica gigas, and Lycium chinense, obtaining an extract thereof, and concentrating and drying the extract under reduced pressure may be performed.
[0037] In the present invention, the composition may contain Cudrania tricuspidata extract: Angelica gigas extract: Lycium chinense extract in a weight ratio of 1:1 to 1000:1 to 500, more specifically in a weight ratio of 1:300 to 800:50 to 400, and even more specifically in a weight ratio of 1:400 to 750:100 to 300.
[0038] In the present invention, the term "female menopausal symptoms" refers collectively to symptoms and diseases that appear in women around menopause as the secretion of estrogen decreases due to ovarian aging, and may include, but are not limited to, hot flashes, sweating, dry skin, vaginal dryness, vaginal atrophy, lower urethral atrophy, vaginitis, cystitis, dysuria, urgency, difficulty concentrating, short-term memory impairment, anxiety, nervousness, memory loss, muscle pain, joint pain, or osteoporosis.
[0039] In the present invention, the composition has estrogen activity and exhibits estrogen receptor (ER) agonist activity, thereby having a therapeutic effect on female menopausal symptoms.
[0041] In a specific embodiment of the present invention, the inventors prepared a Cudrania tricuspidata extract, an Angelica gigas extract, and a Lycium chinense extract, and mixed the extracts in a specific mixing ratio to prepare Cudrania tricuspidata, Angelica gigas, and Lycium chinense extracts.
[0042] In addition, the inventors treated the estrogen receptor-positive breast cancer cell line MCF-7 with a mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense and measured the degree of ER-mediated transcriptional activity. As a result, they confirmed that compared to the case where Cudrania tricuspidata, Angelica gigas, and Lycium chinense extracts were treated individually, when the Cudrania tricuspidata extract: Angelica gigas extract: Lycium chinense extract were mixed in a ratio of 1:400 to 750:100 to 300, the activity increased more than the sum of the ER-mediated transcriptional activities of each extract, showing a synergistic effect (see Fig. 1).
[0043] In addition, the inventors treated the mixed extract to estrogen receptor-positive breast cancer cell line MCF-7 and measured the cell viability. As a result, they confirmed that the cell viability of the mixed extract increased compared to the sum of the cell viability of the extracts of Cudrania tricuspidata, Angelica gigas, and Lycium chinense, showing a synergistic effect (see Fig. 2).
[0044] In addition, the inventors administered the above mixed extract to the endometrial cancer adenocarcinoma cell line Ishikawa at different concentrations and measured the degree of ER-mediated transcriptional activity. As a result, the degree of ER-mediated transcriptional activity with and without administration was significantly lower compared to the transcriptional activity results of the breast cancer cell line MCF-7, confirming that there were almost no symptoms of uterine proliferation, which is one of the side effects of ER agonists (see Fig. 3).
[0045] Therefore, since the mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense of the present invention has estrogen activity and exhibits activity as an ER agonist without side effects, the Cudrania tricuspidata extract, Angelica gigas extract, and Lycium chinense extract of the present invention can be usefully used as active ingredients in a pharmaceutical composition for preventing or treating menopausal symptoms caused by estrogen deficiency in menopausal women.
[0047] The pharmaceutical composition according to the present invention may further include a suitable carrier, excipient, and diluent commonly used in the manufacture of pharmaceutical compositions.
[0048] The pharmaceutical composition according to the present invention may be administered orally or parenterally. When administering parenterally, it is preferable to select a method of administration such as external application to the skin, intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection, but is not limited thereto.
[0049] The pharmaceutical composition according to the present invention may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, external preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods. Carriers, excipients, and diluents that may be included in the composition may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. When formulating, the preparation is typically made using diluents or excipients such as commonly used fillers, volume expanders, binders, humectants, disintegrants, and surfactants. Solid dosage forms for oral administration include tablets, pills, powders, granules, and capsules; these solid dosage forms are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, or gelatin, with mixed herbal medicines. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid dosage forms for oral administration include suspensions, liquids, emulsions, and syrups; in addition to commonly used simple diluents such as water and liquid paraffin, various excipients, such as humectants, sweeteners, flavorings, and preservatives, may be included. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleates.Witepsol, macrogol, Tween 61, cacao gelatin, laurin gelatin, glycerogelatin, etc., may be used as the base for suppositories. In addition, other common additives such as antioxidants, buffers, and bacteriostatic agents may be added as needed.
[0050] The preferred dosage of the pharmaceutical composition according to the present invention varies depending on the absorption rate of the active ingredient in the body, the age and gender of the patient, and the severity of symptoms, but can be appropriately selected by those skilled in the art. However, for a desirable effect, in the case of an oral formulation, it is generally preferable to administer the composition of the present invention to adults at a dose of 0.0001 to 1000 mg / kg per day, preferably 0.001 to 500 mg / kg per day, per body weight. The administration may be performed once a day or divided into several doses. The above dosage does not limit the scope of the present invention in any way.
[0052] The present invention provides a health functional food for preventing or improving symptoms of menopause in women, containing Cudrania tricuspidata extract, Angelica gigas extract, and Lycium chinense extract as active ingredients.
[0053] The above-mentioned Cudrania tricuspidata extract, Angelica gigas extract, and Lycium chinense extract, their mixing ratios, and female menopausal symptoms are identical to the description of the pharmaceutical composition for the prevention or treatment of female menopausal symptoms; therefore, specific descriptions are provided by reference to the above content, and below, only the specific composition of the health functional food will be described.
[0054] Meanwhile, since the mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense of the present invention has estrogen activity and exhibits activity as an ER agonist without side effects, the mixed extract of Cudrania tricuspidata extract, Angelica gigas extract, and Lycium chinense extract of the present invention can be usefully used as an active ingredient in a health functional food to prevent or improve menopausal symptoms caused by estrogen deficiency in menopausal women.
[0056] The three types of extracts of the present invention can be mixed with a food-grade acceptable carrier and provided as a food composition.
[0057] When the three types of extracts of the present invention are used as food or beverage additives, they may be added as is or used together with other foods or food ingredients, and may be used appropriately according to conventional methods. The amount of the mixture of the three types of extracts may be appropriately determined according to the purpose of use (prevention, health, or therapeutic treatment). In the case of long-term consumption for the purpose of health and hygiene or health control, the three types of extracts pose no safety issues, so long-term consumption is possible. There are no special restrictions on the types of food.
[0058] Examples of foods to which the above substances may be added include meat, sausages, bread, chocolates, candies, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes. When formulated as a beverage, the liquid components added in addition to the three types of extracts mentioned above are not limited to, but may contain various flavoring agents or natural carbohydrates as additional ingredients, as in conventional beverages. Examples of the natural carbohydrates mentioned above are monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.), polysaccharides (e.g., conventional sugars such as dextrin, cyclodextrin, etc.), and sugar alcohols such as xylitol, sorbitol, and erythritol. The proportion of the natural carbohydrates is generally about 1 to 20 g, preferably about 5 to 12 g, per 100 ml of the composition of the present invention. Natural flavoring agents [taumarin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.)] and synthetic flavoring agents (e.g., saccharin, aspartame, etc.) other than those described above may be used.
[0059] In addition, the food composition of the present invention may contain various nutritional agents, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and promoters (cheese, chocolate, etc.), pectic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the food composition of the present invention may contain fruit pulp for the production of fruit and vegetable beverages. These ingredients may be used alone or in combination, and the proportion of these additives is generally selected in the range of 0.001 to 50 parts by weight per total weight of the composition.
[0061] The present invention will be explained in detail below through examples, experimental examples, and manufacturing examples.
[0062] However, the following examples, experimental examples, and manufacturing examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples, experimental examples, and manufacturing examples.
[0064] <Example 1> Cudrania tricuspidata ( Cudrania tricuspidata Preparation of ) extract
[0065] Harvested Cudrania Cudrania tricuspidata The fruit was completely frozen at -20°C, dried using a freeze-dryer, and then ground using a grinder. 10 ml of 70% methanol was added to 2 g of the freeze-dried Cudrania tricuspidata fruit powder, and ultrasonic extraction was performed for 15 minutes. The ultrasonically extracted Cudrania tricuspidata extract was centrifuged at 3,000 rpm for 10 minutes, the supernatant was separated, and the supernatant was filtered through a 0.45 µm PTFE-syringe filter for use.
[0067] <Example 2> Angelica ( Angelica sinensis Preparation of ) extract
[0068] The harvested Angelica ( Angelica sinensisThe roots were completely frozen at -20°C, dried using a freeze-dryer, and then ground using a grinder. 10 ml of 70% methanol was added to 2 g of the freeze-dried Angelica root powder, and ultrasonic extraction was performed for 15 minutes. The ultrasonically extracted Cudrania tricuspidata extract was centrifuged at 3,000 rpm for 10 minutes, the supernatant was separated, and the supernatant was filtered through a 0.45 µm PTFE-syringe filter for use.
[0070] <Example 3> Ziziphus jujuba ( Lycii Radicis Cortex Preparation of ) extract
[0071] Obtained *Jigolpi* ( Lycii Radicis Cortex The plant was completely frozen at -20°C, dried using a freeze-dryer, and then ground using a grinder. 10 ml of 70% methanol was added to 2 g of the freeze-dried mulberry bark powder, and ultrasonic extraction was performed for 15 minutes. The ultrasonically extracted mulberry extract was centrifuged at 3,000 rpm for 10 minutes, the supernatant was separated, and the supernatant was filtered through a 0.45 µm PTFE-syringe filter for use.
[0073] <Example 4> Preparation of mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense
[0074] A mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense was prepared by mixing the Cudrania tricuspidata extract prepared in <Example 1>, the Angelica gigas extract prepared in <Example 2>, and the Lycium chinense extract prepared in <Example 3> according to the composition of [Table 1] below.
[0075] Examples Extract Mixture Composition (µg / ml) Extract mixing ratio Cudrania Angelica Jigolpi Cudrania tricuspidata: Angelica: Lycium chinense 4 3 2000 500 0.0015:1:0.25
[0077] <Experimental Example 1> Confirmation of Estrogen Receptor (ER) Agonist Activity of Mixed Extracts of Cudrania tricuspidata, Angelica gigas, and Lycium chinense
[0078] It is known that the biological action of estrogen is mediated by the binding of estrogen to the estrogen receptor (ER) as a ligand, and since the ER acts as a transcription factor and binds to the estrogen response element (ERE), the effect of a therapeutic agent can be monitored by confirming ER-mediated transcriptional activity using an ERE reporter, namely ER-reactive luciferase. Therefore, in order to determine whether a mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense can act as an ER agonist to improve menopausal symptoms caused by estrogen deficiency in menopausal women, the degree of ER-mediated transcriptional activity was measured after treating cells transfected with a plasmid containing ERE-luciferase with a mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense prepared by mixing them at a specific ratio.
[0079] Specifically, estrogen receptor-positive breast cancer cell line MCF-7 purchased from the American Type Culture Collection (ATCC) was cultured using a base medium consisting of DMEM (Dulbecco's modified Eagle's medium) supplemented with non-essential amino acids, antibiotics / antimycotics, sodium pyruvate, and 10% fetal bovine serum. Subculture was performed once a week on average. Cells were cultured using a medium prepared from phenol-red-free DMEM containing stripped serum, which had been treated with dextran-charcoal three times 48 to 60 hours (2 to 3 days) prior to cell seeding. This medium was used continuously until the luciferase assay was completed. The reason for using the above medium is to exclude results caused by estrogen receptor interactions due to the estrogenic properties of phenol-red itself and hormones and growth factors present in large amounts in the serum.
[0080] Next, the cultured breast cancer cell line MCF-7 is inoculated into a 24-well plate one day before transfection (10 5 After cell / well, ERE-luciferase plasmid DNA (0.25 μg / well) was transfected into the breast cancer cell line using Lipofectamine 2000 transfection reagent (Invitrogen).
[0081] As a control group, the Cudrania tricuspidata extract prepared in <Example 1>, the Angelica gigas extract prepared in <Example 2>, and the Lycium chinense extract prepared in <Example 3> were used, and as an experimental group, the mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense prepared in <Example 4> was used, and each extract was tested at a concentration of 200 μg / ml. Meanwhile, cells were treated with a mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense, and after culturing for an additional 24 hours, a luciferase assay was performed. For the luciferase assay, the culture medium was removed, the cells were washed twice with cold PBS, and the cell lysate was extracted using 1X passive lysis buffer (Promega). After mixing 50 µl of the cell lysate with 50 µl of luciferase assay reagent (a solution containing luciferin, which serves as a substrate for luciferase, and a buffer suitable for the enzymatic reaction, Promega), the resulting luminescence intensity was measured using SpectraMax M5 e It was measured using a molecular device. In addition, the %Increase value of the ER-mediated transcriptional activity of the group treated with the mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense relative to the sum of the ER-mediated transcriptional activities of each control group was calculated using the following mathematical formula: %Increase = [(ER-mediated transcriptional activity of the group treated with the mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense - Sum of the ER-mediated transcriptional activities of each control group) / Sum of the ER-mediated transcriptional activities of each control group] × 100.
[0083] As a result, as shown in Figure 1, the % increase value of the mixed extract treatment group was 21.2%, confirming that the ER-mediated transcriptional activity of the mixed extract treatment group was significantly higher than the sum of the ER-mediated transcriptional activity of each of the Cudrania tricuspidata extract treatment group, Angelica gigas extract treatment group, and Lycium chinense extract treatment group treated at the same concentration as that contained in the mixed extract (Figure 1).
[0084] Through the above results, it was confirmed that the mixed extract of the present invention, containing Cudrania tricuspidata extract, Angelica gigas extract, and Lycium chinense extract, exhibits a synergistic effect as an ER agonist.
[0086] <Experimental Example 2> Confirmation of Estrogen-like Activity of Mixed Extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense
[0087] Estrogen activity is known to proliferate cells in which the estrogen receptor (ER) is intrinsically expressed. Therefore, to determine whether a mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense can have an estrogen-like effect, the degree of cell proliferation was measured after treating breast cancer cell line MCF-7 with the mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense.
[0088] Specifically, breast cancer cell line MCF-7 purchased from the American Type Culture Collection (ATCC) was seeded into a 24-well plate and cultured for 24 hours. Then, dimethylsulfoxide (DMSO) was used for the control group, the Cudrania tricuspidata extract prepared in <Example 1>, the Angelica gigas extract prepared in <Example 2>, and the Lycium chinense extract prepared in <Example 3> were used for the comparison group, and the mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense prepared in <Example 4> was used for the experimental group, and the experiment was conducted at a concentration of 200 μg / ml for each extract. Subsequently, the respective extracts were applied to the cells on days 1, 3, and 5 after inoculation, and a MTT assay was performed on day 7 to quantify the number of surviving cells. For the MTT assay, 0.5 mg / mL of MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, and yellow tetrazole were dispensed at a dose of 10 µL per well; after 2 hours, the medium was removed, 100 µL of DMSO was added to dissolve the blue formazan crystal, and SpectraMax M5 was used at 595 nm. e Measurements were taken using a molecular device. In addition, the %Increase value of MCF-7 cell proliferation in the group treated with the mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense, relative to the sum of cell viability in each control group, was calculated using the following formula: %Increase = [(MCF-7 cell proliferation in the group treated with the mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense - Sum of MCF-7 cell proliferation in each control group) / Sum of MCF-7 cell proliferation in each control group] × 100.
[0090] As a result, as shown in Figure 2, the % increase value of the mixed extract treatment group was 31.5%, confirming that the degree of cell proliferation in the mixed extract treatment group was significantly higher than the sum of the degree of cell proliferation in each of the Cudrania tricuspidata extract treatment group, Angelica gigas extract treatment group, and Lycium chinense extract treatment group treated at the same concentration as that contained in the mixed extract (Figure 2).
[0091] Through the above results, it was confirmed that the mixed extract of the present invention, containing Cudrania tricuspidata extract, Angelica gigas extract, and Lycium chinense extract, exhibits a synergistic effect on estrogen-like activity.
[0093] <Experimental Example 3> Confirmation of Safety of Mixed Extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense
[0094] Estrogen activity is known to be directly or indirectly associated with mechanisms such as endometrial cell proliferation, and thus uterine proliferation is recognized as one of the side effects of estrogen compounds. Therefore, in order to determine whether the mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense is safe for human application, the degree of uterine proliferation was measured after administering the mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense to the Ishikawa endometrial adenocarcinoma cell line.
[0095] Specifically, breast cancer cell line MCF-7 and endometrial adenocarcinoma cell line Ishikawa, purchased from the American Type Culture Collection (ATCC), were seeded into a 24-well plate and cultured for 24 hours, after which the estrogen response element (ERE) plasmid gene was transfected. Then, the mixed extract samples of Cudrania tricuspidata, Angelica gigas, and Lycium chinense from <Example 4> were added at concentrations of 125, 250, 500, and 1000 μg, respectively, and after culturing for another 24 hours, a luciferase assay was performed. For the above luciferase activity evaluation, after removing the culture medium, the cells were washed twice with cold PBS, and the cell lysate was extracted using 1X passive lysis buffer (Promega). Then, 50 µl of luciferase assay reagent (a solution containing luciferin, which serves as a substrate for luciferase, and a buffer suitable for the enzymatic reaction, Promega) was mixed with 50 µl of the cell lysate, and the resulting luminescence intensity was measured using SpectraMax M5 e It was measured using a molecular device.
[0097] As a result, as shown in Fig. 3, the level of transcriptional activity of Ishikawa endometrial adenocarcinoma cells increased with concentration, but it was confirmed that the level of increase was about 11 times lower compared to the result of transcriptional activity of breast cancer cell line MCF-7 (Fig. 3).
[0098] Through the above results, it was confirmed that the mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense of the present invention is safe as an ER agonist with no side effects of uterine proliferation.
[0100] Therefore, through the results of the above <Experimental Examples 1> to <Experimental Examples 3>, it was confirmed that the mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense of the present invention has estrogen activity and acts as an ER agonist without side effects. Thus, the mixed extract of Cudrania tricuspidata, Angelica gigas, and Lycium chinense of the present invention can be used in hormone replacement therapy to prevent and treat menopausal symptoms caused by estrogen deficiency in menopausal women.
[0102] The following describes examples of the preparation of each formulation according to the present invention. The following examples are intended to aid in understanding the implementation of the present invention and do not imply that the method of preparing the formulation according to the present invention is limited to the following examples.
[0104] <Preparation Example 1> Preparation of a pharmaceutical formulation
[0105] <1-1> Preparation of Powders
[0106] 2 g of the mixed extract of the present invention
[0107] 1 g lactose
[0108] The above ingredients were mixed and filled into an airtight bag to manufacture a powder.
[0110] <1-2> Preparation of Tablets
[0111] 100 mg of the mixed extract of the present invention
[0112] Microcrystalline cellulose 100 mg
[0113] 100 mg of lactose
[0114] Sodium starch glycolate 18 mg
[0115] Magnesium stearate 2 mg
[0116] After mixing the above ingredients, tablets were manufactured by compressing them according to the conventional method of manufacturing tablets.
[0118] <1-3> Preparation of Capsules
[0119] 100 mg of the mixed extract of the present invention
[0120] 100 mg of corn starch
[0121] 100 mg lactose
[0122] Magnesium stearate 2 mg
[0123] After mixing the above ingredients, a capsule was manufactured by filling it into a gelatin capsule according to a conventional method for manufacturing capsules.
[0125] <1-4> Preparation of pills
[0126] 1 g of the mixed extract of the present invention
[0127] 1.5 g lactose
[0128] 1 g glycerin
[0129] 0.5 g xylitol
[0130] After mixing the above ingredients, the product was prepared according to a conventional method so that each pill weighed 4 g.
[0132] <1-5> Preparation of Granules
[0133] 150 mg of the mixed extract of the present invention
[0134] Soybean extract 50 mg
[0135] 200 mg of glucose
[0136] 600 mg of starch
[0137] After mixing the above ingredients, 100 mg of 30% ethanol was added and dried at 60°C to form granules, which were then filled into a bag.
[0139] <Preparation Example 2> Preparation of food
[0140] <2-1> Preparation of Snacks and Snacks
[0141] 0.5 to 5.0 parts by weight of the mixed extract of the present invention were added to flour, and bread, cake, cookies, crackers, and noodles were manufactured using this mixture to produce health-promoting food.
[0143] <2-2> Manufacturing of Dairy Products
[0144] 5 to 10 parts by weight of the mixed extract of the present invention were added to milk, and various dairy products such as butter and ice cream were manufactured using the milk.
[0146] <2-3> Preparation of Seonsik
[0147] Brown rice, barley, glutinous rice, and Job's tears were gelatinized and dried using a known method, then roasted and ground into a powder with a particle size of 60 mesh using a grinder. Black beans, black sesame seeds, and perilla seeds were also steamed and dried using a known method, then roasted and ground into a powder with a particle size of 60 mesh using a grinder.
[0148] The mixed extract of the present invention was concentrated under reduced pressure in a vacuum concentrator and dried using a spray and hot air dryer. The resulting dried material was ground to a particle size of 60 mesh using a grinder to obtain a dried powder. The dried powders of grains, seeds, and SBE prepared above were mixed in the following proportions to produce a powder.
[0149] Grains (30 parts by weight of brown rice, 15 parts by weight of Job's tears, 20 parts by weight of barley),
[0150] Seeds (7 parts by weight perilla, 8 parts by weight black soybeans, 7 parts by weight black sesame),
[0151] The dried powder of the mulberry extract or its enzymatic hydrolysate of the present invention (3 parts by weight),
[0152] Ganoderma lucidum (0.5 parts by weight), and Rehmannia glutinosa (0.5 parts by weight)
[0154] <Preparation Example 3> Preparation of a beverage
[0155] 1000 mg of the mixed extract of the present invention
[0156] 1000 mg citric acid
[0157] 100 g of oligosaccharide
[0158] 2 g of plum concentrate
[0159] 1 g of taurine
[0160] Add purified water to make a total of 900 ml
[0161] The above ingredients are mixed according to a conventional method for manufacturing health drinks, then stirred and heated at 85°C for about 1 hour, the resulting solution is filtered, obtained in a sterilized 2-liter container, sealed and sterilized, and then refrigerated and used in the manufacture of the health food of the present invention.
[0162] Although the above composition ratio was formulated by mixing ingredients suitable for relatively palatable beverages as a preferred embodiment, the mixing ratio may be arbitrarily modified according to regional and ethnic preferences, such as consumer groups, countries of demand, and intended uses.
Claims
Claim 1 Cudrania Cudrania tricuspidata ) extract, Angelica ( Angelica sinensis ) extract and *Lycium chinense* bark ( Lycii Radicis Cortex A pharmaceutical composition for preventing or treating symptoms of female menopause, comprising an extract as an active ingredient, wherein the symptoms of female menopause are one or more selected from the group consisting of hot flashes, sweating, dry skin, vaginal dryness, vaginal atrophy, lower urethral atrophy, vaginitis, cystitis, dysuria, urinary urgency, concentration disorder, short-term memory disorder, anxiety, nervousness, memory loss, and muscle pain. Claim 2 A pharmaceutical composition for preventing or treating symptoms of menopause in women, characterized in that, in claim 1, the extract is extracted with water, a C1 to C2 lower alcohol, or a mixed solvent thereof. Claim 3 A pharmaceutical composition for preventing or treating symptoms of menopause in women, characterized in that, in paragraph 2, the extract is extracted with one or more solvents selected from the group consisting of water, methanol, ethanol, and mixed solvents thereof. Claim 4 A pharmaceutical composition for preventing or treating symptoms of menopause in women, characterized in that, in claim 1, the Cudrania tricuspidata and Angelica gigas extracts are one or more extracts selected from flowers, branches, stems, leaves, fruits, above-ground parts, rhizomes, and roots. Claim 5 A pharmaceutical composition for preventing or treating symptoms of menopause in women, characterized in that, in claim 1, the composition contains Cudrania tricuspidata extract: Angelica gigas extract: Lycium chinense extract in a weight ratio of 1:1 to 1000:1 to 500. Claim 6 A pharmaceutical composition for preventing or treating symptoms of menopause in women, characterized in that, in claim 1, the composition contains Cudrania tricuspidata extract: Angelica gigas extract: Lycium chinense extract in a weight ratio of 1:300 to 800:50 to 400. Claim 7 delete Claim 8 A pharmaceutical composition for preventing or treating symptoms of menopause in women, characterized in that, in claim 1, the composition is an estrogen receptor agonist. Claim 9 A pharmaceutical composition for preventing or treating symptoms of menopause in women, characterized in that, in claim 1, the composition has estrogen activity. Claim 10 A health functional food for preventing or improving symptoms of menopause in women, containing Cudrania tricuspidata extract, Angelica gigas extract, and Lycium chinense extract as active ingredients, wherein the symptoms of menopause in women are one or more selected from the group consisting of hot flashes, sweating, dry skin, vaginal dryness, vaginal atrophy, lower urethral atrophy, vaginitis, cystitis, dysuria, urinary urgency, concentration disorder, short-term memory disorder, anxiety, nervousness, memory loss, and muscle pain. Claim 11 A health functional food for preventing or improving symptoms of menopause in women, characterized in that, in claim 10, the extract is extracted with water, a C1 to C2 lower alcohol, or a mixed solvent thereof. Claim 12 A health functional food for preventing or improving symptoms of menopause in women, characterized in that, in claim 10, the above-mentioned Cudrania tricuspidata and Angelica gigas extracts are one or more extracts selected from flowers, branches, stems, leaves, fruits, above-ground parts, rhizomes, and roots. Claim 13 A health functional food for preventing or improving symptoms of menopause in women, characterized in that, in claim 10, the above health functional food contains Cudrania tricuspidata extract: Angelica gigas extract: Lycium chinense extract in a weight ratio of 1:1 to 1000:1 to 500. Claim 14 delete Claim 15 A food composition for preventing or improving symptoms of menopause in women, containing Cudrania tricuspidata extract, Angelica gigas extract, and Lycium chinense extract as active ingredients, wherein the symptoms of menopause in women are one or more selected from the group consisting of hot flashes, sweating, dry skin, vaginal dryness, vaginal atrophy, lower urethral atrophy, vaginitis, cystitis, dysuria, urinary urgency, concentration disorder, short-term memory disorder, anxiety, nervousness, memory loss, and muscle pain. Claim 16 delete
Citation Information
Patent Citations
Composition for Preventing, Treating or Improving Sex Hormone-related Diseases or Symptoms comprising Extract from Cudrania tricuspidata or Mixture of Extract from Cudrania tricuspidata and Extract from Lepidium meyenii
KR1020150029852A
